Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study gives kids with relapsed cancer access to cutting-edge drugs outside clinical trials

NCT ID NCT04477681

Knowledge-focused Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study collects real-world data on how well new cancer drugs work in children, teens, and young adults up to age 25 who have relapsed or stopped responding to treatment and cannot join a clinical trial. Researchers will track safety and effectiveness of targeted therapies, immunotherapies, and chemotherapies used in everyday medical practice. The goal is to improve access to innovative treatments and gather evidence to guide future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2020

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Any child, adolescent or young adult, treated for a pediatric tumor or leukemia, in therapeutic failure or relapse without standard treatment option, not eligible / refusal of inclusion in a clinical study open on the territory and treated with an innovative drug within the framework of compassionate use or outside marketing authorization, in one of the centers of the SFCE (Société Française des Cancers de l' Enfant).

Ages

Up to 25 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≤ 25 years old at the time of inclusion in the study * Patient with a pediatric tumor or leukemia in therapeutic failure or relapse without standard therapeutic options. Exceptionally, patients on the first line of treatment without standard therapeutic options may also be included (eg g: inoperable plexiform neurofibroma and MEK inhibitors, childhood fibrosarcoma and NTRK inhibitors). * Patient not eligible for an early phase clinical trial open to inclusion on French territory or refusal of inclusion * Patient treated with a new drug discussed at a RCPPI as part of a compassionate use issued by the ANSM or an off-label prescription of a drug of interest already authorized in adults. * Patients treated in one of the SFCE centers authorized to prescribe chemotherapy * Patient who did not object to participate after being informed of the study. The patient must be able and willing to cooperate in the study. Exclusion Criteria: * Patient included in an early phase clinical trial open to inclusions on French territory. * Oral refusal to participate by the patient or their legal representatives, in reading the information note specific to the study * Patient under guardianship or curatorship, deprived of liberty or in the impossibility of expressing opposition to participating in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pediatric cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

childhood malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pediatric cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    32 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Amiens

    RECRUITING

    Amiens, France

  • CHU Angers

    RECRUITING

    Angers, France

  • CHU Besançon

    RECRUITING

    Besançon, France

  • CHU Bordeaux

    RECRUITING

    Bordeaux, France

  • CHU CAEN

    RECRUITING

    Caen, France

  • CHU Clermont-Ferrand

    RECRUITING

    Clermont-Ferrand, France

  • CHU Dijon

    RECRUITING

    Dijon, France

  • CHU Grenoble

    RECRUITING

    Grenoble, France

  • CHU La Réunion

    RECRUITING

    Saint-Denis, France

  • CHU Lille

    RECRUITING

    Lille, France

  • CHU Limoges

    RECRUITING

    Limoges, France

  • CHU Lyon

    RECRUITING

    Lyon, France

  • CHU Montpellier

    RECRUITING

    Montpellier, France

  • CHU Morvan

    RECRUITING

    Brest, 29200, France

  • CHU Nancy

    RECRUITING

    Nancy, France

  • CHU Nantes

    RECRUITING

    Nantes, France

  • CHU Nice

    RECRUITING

    Nice, France

  • CHU Poitiers

    RECRUITING

    Poitiers, France

  • CHU Reims

    RECRUITING

    Reims, France

  • CHU Rennes

    RECRUITING

    Rennes, France

  • CHU Rouen

    RECRUITING

    Rouen, France

  • CHU Saint-Etienne

    RECRUITING

    Saint-Etienne, France

  • CHU Strasbourg

    RECRUITING

    Strasbourg, France

  • CHU Toulouse

    RECRUITING

    Toulouse, France

  • CHU Tours

    RECRUITING

    Tours, France

  • Centre Léon Bérard

    RECRUITING

    Lyon, France

  • Centre Oscar Lambret

    RECRUITING

    Lille, France

  • Gustave Roussy

    RECRUITING

    Villejuif, Val de Marne, 94805, France

  • Hôpital Armand Trousseau

    RECRUITING

    Paris, France

  • Hôpital Robert-Debré

    RECRUITING

    Paris, France

  • Hôpital de La Timone

    RECRUITING

    Marseille, France

  • Institut Curie

    RECRUITING

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.